

Adenosine A₁ Receptors Selectively Modulate Oxygen-Induced Retinopathy at the Hyperoxic and Hypoxic Phases by Distinct Cellular Mechanisms

Shuya Zhang,¹ Haiyan Li,¹ Bo Li,¹ Dingjuan Zhong,¹ Xuejiao Gu,² Lingyun Tang,² Yanyan Wang,² Cun Wang,² Rong Zhou,² Yan Li,¹ Yan He,¹ Mozi Chen,¹ Yuqing Huo,^{3,4} Xiao-Ling Liu,² and Jiang-Fan Chen^{1,5}

¹Institute of Molecular Medicine, School of Optometry and Ophthalmology and Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China

²State Key Laboratory Cultivation Base and Key Laboratory of Vision Science, Ministry of Health, China and Zhejiang Provincial Key Laboratory of Ophthalmology and Optometry, Wenzhou, Zhejiang, China

³Vascular Biology Center, Department of Cellular Biology and Anatomy, Medical College of Georgia, Georgia Regents University, Augusta, Georgia, United States

⁴Drug Discovery Center, Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen, China

⁵Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, United States

Correspondence: Jiang-Fan Chen, School of Ophthalmology and Optometry and Eye Hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou, Zhejiang, China 325027; chenjf555@gmail.com.

SZ and HL contributed equally to the work presented here and should therefore be regarded as equivalent authors.

Submitted: May 1, 2015

Accepted: November 4, 2015

Citation: Zhang S, Li H, Li B, et al. Adenosine A₁ receptors selectively modulate oxygen-induced retinopathy at the hyperoxic and hypoxic phases by distinct cellular mechanisms. *Invest Ophthalmol Vis Sci*. 2015;56:8108–8119. DOI:10.1167/iov.15-17202

PURPOSE. We critically evaluated the role of the adenosine A₁ receptor (A₁R) in normal development of retinal vasculature and pathogenesis of retinopathy of prematurity (ROP) by using the A₁R knockout (KO) mice and oxygen-induced retinopathy (OIR) model.

METHODS. Mice deficient in A₁Rs and their wild-type (WT) littermates were examined during normal postnatal development or after being subjected to 75% oxygen from postnatal day (P) 7 to P12 and to room air from P12 to P17 (OIR model of ROP). Retinal vascularization was examined by whole-mount fluorescence and cross-sectional hematoxylin-eosin staining. Cellular proliferation, astrocyte and microglial activation, and tip cell function were determined by isolectin staining and immunohistochemistry. Apoptosis was determined by TUNEL assay.

RESULTS. Genetic deletion of the A₁R did not affect normal retinal vascularization during postnatal development with indistinguishable three-layer vascularization patterns in retina between WT and A₁R KO mice. In the OIR model, genetic deletion of the A₁R resulted in stage-specific effects: reduced hyperoxia-induced retinal vaso-obliteration at P12, but reduced avascular area and attenuated hypoxia-induced intraretinal revascularization without affecting intravitreal neovascularization at P17 and reduced avascular areas in retina at P21. These distinct effects of A₁Rs on OIR were associated with A₁R control of apoptosis mainly in inner and outer nuclear layers at the vaso-obliterative phase (P12) and the growth of endothelium tip cells at the vasoproliferative phase (P17), without modification of cellular proliferation, astrocytic activation, and tissue inflammation.

CONCLUSIONS. Adenosine A₁ receptor activity is not required for normal postnatal development of retinal vasculature but selectively controls hyperoxia-induced vaso-obliteration and hypoxia-driven revascularization by distinct cellular mechanisms.

Keywords: adenosine A₁ receptor, oxygen-induced retinopathy, proliferative retinopathy, retinal revascularization, neovascularization, endothelial tip cells, vaso-obliteration

Retinopathy of prematurity is the most common cause of blindness in childhood.¹ This sight-threatening disease is characterized by two critical phases, hyperoxia- and inflammation-induced damage to retinal vessels and vaso-obliteration followed by hypoxia-driven physiological revascularization and pathologic neovascularization, the processes largely driven by hypoxia-induced factor-1 α (HIF-1 α) signaling pathway and vascular endothelial growth factor (VEGF) levels in retina.^{1,2} Conventional therapies for ROP are limited to laser and cryosurgery, which ablate the avascular retina to prevent retinal detachment caused by ROP.³ However, the effects of ablative laser therapy are limited and are associated with destruction to retina, causing clinically significant loss of visual field. Anti-VEGF therapy (e.g., intravitreal injection of anti-

VEGF-A antibody bevacizumab) has been proposed³ and has recently been tested in a randomized, controlled, and multicenter trial involving 150 infants, which showed reduction of the recurrence rate,⁴ but the efficacy of intravitreal bevacizumab remains unclear with reported persistent avascular retina⁵ and recurrent intravitreal neovascularization.⁶ Importantly, VEGF acts not only as an angiogenic factor, but also as a neurotrophic factor during retinal development. Thus, there are concerns on the unintended effects of anti-VEGF agents on delayed growth and retinal vasculature development of preterm infants.^{7,8}

Current therapeutic development of ROP focuses on directly targeting VEGF and HIF-1 α signaling pathway.^{1,2,4,9} However, cellular responses to hypoxia are characterized by robust

increases in extracellular adenosine production (up to 100-fold) and signaling events through the markedly induced adenosine receptors (up to 50-fold) locally.¹⁰ For example, in a canine model of ROP, the expression of 5' nucleotidase (CD73, an enzyme responsible for generating extracellular adenosine) and adenosine A_{2A} receptor (A_{2A}R) was suppressed during the hyperoxic phase, but markedly increased in hypoxic retina, supporting the possible involvement of adenosine-A_{2A}R signaling in retinal pathologic angiogenesis.¹¹⁻¹⁴ Increased adenosine-adenosine receptor signaling in hypoxic retina not only constitutes a defense mechanism to protect retina by modulating neuroinflammation, cell death, and promoting angiogenesis, but also offers an opportunity of targeting pathologic angiogenesis of ROP with minimal effects on normal retinal vascular development. In support of this view, we have recently demonstrated that genetic inactivation of the A_{2A}R attenuated hypoxia-induced pathologic angiogenesis without affecting normal postnatal retinal vascularization.¹⁵ Therapeutic potential of adenosine receptor-based therapy for ROP is supported by the ability of adenosine receptors to modulate inflammation, neuroprotection, and angiogenesis in retina through activation of four G-protein-coupled receptors, namely, A₁, A_{2A}, A_{2B}, and A₃, all of which have been detected in retina.^{16,17} Increased adenosine acting at A_{2A}Rs suppresses neuroinflammation and protects against diabetic retinopathy (DR)¹⁸ and traumatic optic neuropathy,¹⁹ through control of retinal microglial function and production of proinflammatory cytokines^{20,21}; studies with genetic inactivation of the A_{2A}R,¹⁵ with A_{2B}R antagonists²²⁻²⁴ and with ribozyme approach to inactivating A_{2B}Rs, demonstrate that adenosine acting at the A_{2A} and A_{2B} receptors promotes pathologic angiogenesis in retina through modulating VEGF level.²⁵ The translational potential of adenosine receptor-based therapy for controlling proliferative retinopathy is substantiated by a clinical potential, since a recent large clinical trial of 2006 infants has demonstrated that treatment with caffeine, a nonselective adenosine receptor antagonist, reduces ROP-related problems after 2-year follow-up,²⁶ and by genetic identification of the variants of the human A_{2A}R gene that are associated with reduced risk of developing DR in a prospective study.²⁷

Several studies of adenosine receptor control of retinal vascularization have focused on the A_{2A}R effect,^{11,15,18} with some on the A_{2B} receptor.²⁵ Adenosine A₁ receptor (A₁R) mRNA and ligand binding are detected in developing retina.¹⁷ However, the A₁R effect on retinal vascularization is largely unknown. As an important step in developing adenosine receptor-based treatment for ROP, we critically evaluated the role of the A₁R in normal development of retinal vasculature and pathogenesis of proliferative retinopathy by using the A₁R knockout (KO) mice and oxygen-induced retinopathy (OIR) model. Our characterization of the A₁R KO and wild-type (WT) mice in normal and OIR model demonstrated for the first time that A₁R activity did not affect normal retinal vascular development, but distinctly controlled hyperoxia-induced vaso-obliteration at P12 and hypoxia-induced revascularization at P17 by acting at A₁Rs in distinct cellular elements.

MATERIALS AND METHODS

Congenetic A₁R KO and WT Littermates in C57BL/6 Background

All experimental procedures were conducted in accordance with the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research and the Animal Experimentation Regulation of

Wenzhou Medical University. Generation of congenic A₁R KO mice and WT littermates has been described previously.²⁸ Heterozygous A₁R KO (A₁R^{+/-}) mice were then interbred to generate homozygous A₁R KO (A₁R^{-/-}), heterozygous A₁R KO (A₁R^{+/-}), and WT littermates (A₁R^{+/+}). The mouse genotype was determined by PCR analysis of genomic DNA extracted from mouse tails. Genetic deletion of the A₁R did not affect normal development and most physiological measurements including the body weight, heart rate, blood pressure and body temperature²⁸ and survival rate in this study.

Mouse Model of Oxygen-Induced Retinopathy

The mouse model of OIR was performed according to the protocol as previously described by Smith and colleagues.²⁹ Briefly, pups with their dams were kept in a 75% ± 2% oxygen chamber for 5 days from postnatal day (P) 7 to P12. Nursing mothers were prepared to replace dams for feeding pups every 12 hours during the hyperoxic stage (P7-P12). At P12, the animals were returned to room air for 5 days (from P12 to P17). Age-matched mice raised in room air (P0-P17) were used as the "room air" control group for study of normal postnatal development retinal vascularization.

Fluorescence Immunostaining in Whole-Mount Retinas

Fluorescence staining of whole-mounted retinas was performed as previously described.³⁰ Eyes were fixed in 4% paraformaldehyde and the retinas were dissected and stained with 10 µg/mL isolectin B₄ (Molecular Probes, Life Technologies, Carlsbad, CA, USA) after being blocked and permeabilized. The retinas were then incubated with anti-gliar fibrillary acidic protein (GFAP) mouse monoclonal antibody (1:500; Sigma-Aldrich Corp., St. Louis, MO, USA) for 12 hours at 4°C, followed by incubation with fluorescence-conjugated second antibody (1:500; Invitrogen, Life Technologies) for 2 hours, and then whole-mounted. Eight nonoverlapping and randomly selected microscopic fields per retina were imaged by confocal scanning laser microscopy (LSM 710; Carl Zeiss, Oberkochen, Germany) to assess the formation of endothelial tip cells.

To assess normal postnatal development of retinal angiogenesis, A₁R KO pups and WT littermates (breeding in room air) were killed and the eyes were harvested at P3, P5, P7, P12, and P17. Whole-mount retinas were stained with isolectin B₄. The development of superficial vascular layer from P0 to P7 was quantified as the ratio of vascular area to total retinal area. Three nonoverlapping and randomly selected microscopic fields per retina and whole-mounted retina were assessed for morphology and distribution of retinal vessels from P7 to P17.

Neovascular Nuclei Quantification

To quantify neovascular nuclei, eyes were fixed in 4% paraformaldehyde, embedded in paraffin, sectioned (5 µm), and stained with hematoxylin-eosin. The nuclei beyond the internal limiting membrane on the vitreous side were defined as neovascular nuclei and counted by an investigator in a blinded manner.

TUNEL Staining for Detection of Cell Apoptosis

The TUNEL staining was performed by using a commercial in situ cell death detection kit and following the procedure of the manufacturer's manual (Roche Diagnostics, Basel, Switzerland). The TUNEL-positive cells were counted from three sections crossing the optic nerve per retina to quantify the change of TUNEL signal.

Immunofluorescence Analysis

At P17, mouse eyes were dissected and embedded in paraffin. After being deparaffinized and heated in 10 mM sodium citrate for antigen repairing, retinal paraffin sections were blocked and permeabilized and then were incubated with anti-proliferating cell nuclear antigen (PCNA) rabbit polyclonal antibody (1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-GEAP mouse monoclonal antibody (1:500; Sigma-Aldrich Corp.), or anti-Iba-1 rabbit monoclonal antibody (Wako, Chuo-ku, Osaka, Japan) overnight at 4°C. Fluorescence-conjugated second antibodies (1:500; Invitrogen, Life Technologies) were applied to detect the positive signals. The GFAP/PCNA-positive cells were counted from three sections crossing the optic nerve per retina.

Quantitative Analysis of A₁R mRNA Levels

Adenosine A₁ receptor mRNA level in retina harvested at P17 was done by the quantitative real-time polymerase chain reaction (qPCR) procedure as we have described previously¹⁵ using the following forward and reverse primers for A₁R mRNA: 5'-CATCCTGGCTCTGCTTGCTATT-3' and 5'-TTGGCTATCCAGGCTTGTTCC-3'.

Statistical Analysis

All data were expressed as mean ± SEM. Statistical analyses were conducted by using Student's *t*-test, with *P* < 0.05 being considered statistically significant.

RESULTS

Genetic Deletion of the A₁R Did Not Affect the Normal Development of Retinal Vascularization in Mice

To determine the effect of A₁R gene deletion on normal development of retinal vascularization, we analyzed development of the retinal vascular networks at P3, P7, P12, and P17 of homozygous A₁R KO (A₁R^{-/-}) and WT (A₁R^{+/+}) littermates by fluorescein staining of whole-mounted retinas (Fig. 1A). At P3, the vessels grew radially from the optic nerve head toward the edge of the retina and became progressively interconnected and formed an initial superficial vascular layer. At P5, the deep vascular layer was apparent under the superficial layer, and the vasculature of both WT and A₁R KO mice covered approximately half of the entire retinal area (data not shown). At P7, the average vascular area ratio of the WT and A₁R KO group was 78% and 79%, respectively. At P12, the vasculature covered all the retina for WT and A₁R KO mice, and an intermediate vascular layer developed between the superficial and deep layer. Quantitative analysis revealed that the vascular area at P3 (*n* = 3/group) and P7 (*n* = 3/group) was comparable between WT and A₁R KO mice (Fig. 1A). At P12 and P17, retinal vascularization was near complete and the arborous pattern of retinal vasculature formed over the entire retina with very few avascular areas. Thus, we adapted “branch point” analysis³¹ for quantification of retinal vascularization at P12 and P17. Importantly, branch point analysis showed that retinal vascularization was indistinguishable between WT and A₁R KO mice at P12 (*n* = 6/group) and P17 (*n* = 8/group), indicating that the superficial retinal vasculature grew with similar rates with indistinguishable patterns of the vessel distribution between WT and A₁R KO mice. Moreover, distinct morphologies of three vessel layers were also observed under the confocal scanning laser microscopy at P12 and P17 (Fig. 1B). Arterioles

in the superficial layer had numerous dichotomous branches. The vessels in the intermediate layer presented short capillary segments. The vessels in the deep layer formed anastomotic grids. Similarly, the morphology and distribution of retinal blood vessels were indistinguishable between WT and A₁R KO mice.

Collectively, quantitative analysis of retinal vascularization under room air with total 20 WT and 20 A₁R KO mice at different stages (P3, P7, P12, and P17) demonstrates that A₁R activity is not required for normal postnatal development of retinal vascularization in mice.

Genetic Deletion of A₁Rs Reduced Hyperoxia-Induced Retinal Vascular Regression and Cellular Apoptosis at P12

As the first evidence for the involvement of A₁R in OIR, we found that A₁R mRNA in retina of OIR harvested at P17 was markedly reduced compared to the room air condition (*n* = 8, *P* < 0.01) (Fig. 2). This reduction of A₁R mRNA may reflect the reduced protective effect by adenosine acting at A₁Rs in retina.

To assess the effect of A₁R gene deletion at the hyperoxic stage of OIR, we analyzed the vascular regression of WT and A₁R KO mice in whole-mounted retinas with isolectin B₄ staining. Both WT and KO groups clearly revealed large areas of vaso-obliteration in the central retina (Fig. 3A). Quantitative analysis of retinal vaso-obliteration showed that the percentage of avascular areas of total retina in the A₁R KO group was significantly smaller than that of the WT group by ~20% (6.64% absolute difference over 33.23% of total avascular area = ~20%) (Fig. 3B), indicating that A₁R activation increased hyperoxia-induced retinal vaso-obliteration.

Vaso-obliteration in OIR is a result of neuronal and endothelial apoptosis induced by a combination of direct toxicity of reactive oxygen species to neurons and a downregulation of HIF-1 α -dependent VEGF expression to endothelial cells.³² We performed TUNEL analysis to determine whether the larger avascular region in WT mice at P12 was attributed to neuronal and endothelial apoptosis. Consistent with other studies,³³⁻³⁵ TUNEL-positive signals were detected within the inner nuclear layer (INL; mainly neurons such as amacrine cells and bipolar cells) and outer nuclear layer (ONL) of the avascular area, as well as the ganglion cell layer (GCL) of both WT and A₁R KO groups. Furthermore, TUNEL signal was detected in both INL and ONL layers but largely segregated from the CD31⁺ cells (a marker for endothelium cells) with only very few TUNEL/CD31 costaining signals, indicating that apoptosis was mainly attributed to neuronal apoptosis in retina (Figs. 3C, 3D). Quantitative analysis showed that TUNEL-positive cells were significantly higher in WT mice than A₁R KO mice at P12 (Fig. 3E). Thus, A₁R gene deletion reduces avascular areas at least partly by reducing hyperoxia-induced neuronal apoptosis in retina.

Genetic Deletion of A₁Rs Attenuated Hypoxia-Induced Intraretinal Revascularization but Not Intravitreal Neovascularization at P17

In contrast to the reduced avascular area of A₁R KO mice at P12, quantitative analysis revealed that the A₁R KO mice in fact had increased avascular area, compared to WT group, at P17 (Figs. 4A, 4B). This increased avascular area in A₁R KO mice at P17 could likely be attributed to a perturbation of revascularization in A₁R KO mice at the hypoxic phase. We also investigated the effect of A₁R KO on pathologic angiogenesis and showed that there was no significant difference in neovascularization tufts toward the vitreous and neovascular





FIGURE 1. Genetic inactivation of A₁Rs does not affect the normal development of retinal vessels in mice. (A) The development of retina vasculature of WT and A₁R KO mice at P3, P7, P12, and P17 in room air was visualized by isolectin B4 staining in whole-mount retinas. Vascularized areas and whole retinal surface are shown by *yellow dotted line* and *white dotted line*, respectively. The superficial vascularized areas of retinas at P3 (*n* = 3/group) and P7 (*n* = 3/group) were quantified as a percentage of the whole retinal area. At P12 (*n* = 6/group) and P17 (*n* = 8/group), “branch point” analysis was used for quantification of retinal vascularization under room air. Data are presented as mean ± SEM. Scale bar: 500 µm. (B) The distributions of three retinal vascular layers were displayed in distinct confocal planes. The retinal images from P12 and P17 of WT and A₁R

KO in room air were examined by isolectin B₄ staining of whole-mount retinas. The development of morphology and distribution of superficial, intermediate, and deep plexuses were indistinguishable between WT and A₁R KO mice. Scale bar: 50 μm.

nuclei that formed at the hypoxia phase between A₁R KO and WT groups (Figs. 4A–D). Furthermore, we also analyzed the expression of PCNA, an indicator of cell proliferation, in retina at P17. Consistent with earlier studies,^{15,36} we detected PCNA-positive signals mainly in the superficial vasculature and neovascular tufts surrounding the lumen in the GCL of WT and A₁R KO mice (Fig. 4E). However, the numbers of PCNA-positive cells were indistinguishable between A₁R KO and WT mice at P17, consistent with the lack of A₁R KO on neovascularization tufts (Fig. 4F). Additional analysis showed that scatter TUNEL-positive cells were detected in retina (mainly in the inner and outer nuclear layer) and largely segregated from CD31⁺ cells (Figs. 4G, 4H). There was no difference in retinal TUNEL-positive cells between WT and A₁R KO groups, indicating that the reduced revascularization was not due to increased apoptosis (Fig. 4I). These results showed that at the hypoxic phase, A₁R activation promoted intraretinal revascularization without affecting intravitreal neovascularization, an effect not being attributed to cellular apoptosis or endothelial cellular proliferation in retina.

Genetic Deletion of the A₁R Did Not Affect the Number of Microglial Cells and Astrocytes but Reduced the Formation of Endothelial Tip Cells to Attenuate Intraretinal Revascularization in Hypoxia Phase

We further sought to identify the cellular mechanisms underlying the effects of A₁R activation on promoting revascularization by analyzing function of microglial cells, astrocytes, and endothelial tip cells in retina of WT and A₁R KO mice at P17 of OIR.

Immunohistochemistry analysis of Iba-1 expression in retina showed that microglial activation in retina (mainly in the GCL and INL layers) was indistinguishable between A₁R KO and WT littermates (Figs. 5A, 5B). Thus, inflammatory response (as indirectly indicated by microglial activation) is unlikely a major contributing factor in A₁R control of retinal vascularization and retinopathy. Furthermore, retinal astrocytes participate in angiogenesis in response to hypoxia through their high

expression of VEGF³⁷ and their support for the growth of the leading edge of the developing superficial vascular network.^{38,39} Consistent with previous studies,⁴⁰ GFAP-positive cells were mainly detected in the GCL of retina by immunofluorescence staining. However, GFAP-positive astrocytes in retina were not significantly affected by the genetic inactivation of A₁R (Figs. 5C, 5D). Endothelial tip cells play an important role during angiogenesis by sensing the VEGF gradient produced by astrocytes and by leading the extension of typical filopodia in retinal sprout tips. We therefore further evaluated the formation of endothelial tip cells in retina of WT and A₁R KO groups at P17 of OIR. As seen in Figures 5E and 5F, tip cell filopodia adhered to GFAP-positive astrocytes. Quantitative analysis revealed that the number of endothelial tip cells in retina was significantly reduced in A₁R KO group compared with WT group (Fig. 5G). This finding suggests that A₁R activation enhanced function of endothelial tip cells to promote hypoxia-induced revascularization in retina at P17 of OIR.

Lastly, we analyzed avascular area of A₁R KO and WT littermates of OIR at P21. In contrast to the A₁R KO effect at P17, the avascular area in retina was in fact smaller in A₁R KO than in their WT littermates (Figs. 6A, 6B; *n* = 7 per group), indicating that A₁R activation at the P17 to P21 period apparently slows down normal vascularization of retina in OIR model. Thus, A₁R inactivation exerted distinct effects on retinal vascularization at P12, P17, and P21, likely depending on the different levels of adenosine and different cellular populations involved in these different stages of OIR.

DISCUSSION

Adenosine A₁ Receptor Activity Selectively Modulates Oxygen-Induced Retinopathy Without Affecting Normal Retinal Vascular Development

One of the critical concerns in developing therapeutic strategy for treating ROP is to achieve maximal therapeutic effect on proliferative retinopathy with minimal unintended side effects on neurovascular development in retina. In agreement with our previous finding that A_{2A}R inactivation selectively modulates pathologic angiogenesis without affecting normal retinal vasculature development,¹⁵ genetic deletion of A₁R activity preferentially affected retinal vascularization under pathologic condition of OIR, but postnatal retinal vascularization developed normally with typical morphology, density, and distribution of retinal vessels from P3 to P17 in the absence of the A₁R (Fig. 1). This finding reinforces our contention that interruption of adenosine signaling through A₁R and A_{2A}R has no effect on normal retinal vascular development. This selectivity is further supported by the finding that A₁R mRNA was reduced in retina of OIR model compared to that of room air at P17. The finding confers a critical advantage for the proposed adenosine receptor-based therapeutic strategy over other treatment strategies (such as anti-VEGF antibody), since activity of these molecular targets may be necessary not only for pathologic angiogenesis, but also for normal retinal vascularization during development.⁴¹

This A₁R and A_{2A}R selective control of pathologic retinal vasculature growth in OIR may be in part attributed to the surge of extracellular adenosine and the marked induction of adenosine receptors in response to hypoxia.¹⁰ In models of




Figure 2. Adenosine A₁ receptor mRNA level was reduced in retina of OIR compared to that of room air at P17. Retina of OIR and room air was dissected and harvested at P17, and A₁R mRNA expression in retina was determined by qPCR analysis. Compared to the room air group, A₁R mRNA in retina of OIR was markedly reduced (Fig. 2, *n* = 8/group). Data are presented as the mean ± SEM. **P* < 0.05, Student's *t*-test.




FIGURE 3. Genetic deletion of A₁Rs reduced hypoxia-induced retinal vascular regression and cellular apoptosis at P12. (A) Retinal blood vessels of both WT and KO groups were visualized by isolectin B4 staining of whole-mount retinas at P12 of OIR. The whole retinal surface is shown by *white dotted line*. Avascular area is indicated as *yellow*. Scale bar: 500 μm. (B) Avascular area (%) was quantified as a percentage of the whole retinal surface ($n = 7$ retinas from seven WT mice and $n = 9$ retinas from nine A₁R KO mice). Data are presented as the mean \pm SEM. * $P < 0.05$, Student's *t*-test. (C, D) The apoptotic cells in retinal cross-sections of WT and A₁R KO mice were detected by TUNEL staining at P12 of OIR. TUNEL-positive cells are indicated by *yellow arrows*. TUNEL signals were detected mainly in INL and ONL layers of retina in both WT and A₁R KO mice. Coimmunostaining of TUNEL and CD31 (a marker for endothelial cell) revealed that CD31⁺ cells (*white arrowhead*) were largely segregated from the TUNEL signal (*yellow arrowhead*) with little coimmunostaining of TUNEL/CD31 (*yellow arrow*). Scale bar: 20 μm. (E) The TUNEL-positive cells of WT and A₁R KO groups were quantified. Data are presented as mean \pm SEM. * $P < 0.05$ comparing A₁R KO group with WT group ($n = 6$ retinas from six WT mice and $n = 6$ retinas from six A₁R KO mice).

ROP, hypoxia triggers the surge in extracellular adenosine as a result of transcriptional induction of CD73 and equivalent nucleotide transporter 1 as well as suppression of adenosine kinase, thereby elevating the capacity of local tissues for

extracellular adenosine production.^{11,42} Adenosine accumulating locally during hypoxia permits the local control of retinal vessel growth.¹¹ Furthermore, pathologic conditions are accompanied by the increases of local inflammatory




FIGURE 4. Genetic deletion of A₁Rs reduced hypoxia-induced physiological intraretinal revascularization without affecting intravitreal neovascularization, hypoxia-induced cellular apoptosis, and proliferation at P17. (A) Retinal vasculature was stained by isolectin B4 of whole-mount retinas at P17 of OIR. Whole retinal area was circumscribed by *white dotted line* ($n = 13$ retinas from 13 WT mice and $n = 12$ retinas from 12 A₁R KO mice). Avascular area and the areas of neovascularization tufts were highlighted in *yellow* and *green*, respectively. *Scale bar*: 500 μ m. (B) The avascular area (%) was quantified as the ratio of central avascular area to whole retinal area. The neovascularization tufts area (%) was quantified as a percentage of whole retinal area. (C) Retinal pathologic angiogenesis at P17 was observed by using hematoxylin and eosin staining ($n = 7$

retinas from 7 WT mice and $n = 7$ retinas from 12 A₁R KO mice). Nuclei on the vitreal side of the inner limiting membrane are indicated by *black arrows*. Scale bar: 50 μm . (D) The number of neovascular nuclei was quantified. (E) Hypoxia-induced retinal cellular proliferation of WT and A₁R KO mice at P17 of OIR was detected by PCNA immunohistochemistry ($n = 7$ retinas from 7 WT mice and $n = 7$ retinas from 12 A₁R KO mice). The PCNA-positive cells are indicated by *yellow arrows*. Scale bar: 20 μm . (F) The quantification of PCNA-positive cells of WT and A₁R KO mice is shown. (G, H) Hypoxia-induced apoptotic cells of WT and A₁R KO retinas at P17 of OIR were assayed by TUNEL staining and costaining with CD31. TUNEL-positive cells are indicated by *yellow arrows* ($n = 14$ retinas from 14 WT mice and $n = 15$ retinas from 15 A₁R KO mice). Coimmunostaining of TUNEL and CD31⁺ cells revealed that CD31⁺ cells (*white arrowhead*) were largely segregated from the TUNEL signal (*yellow arrowhead*) with little coimmunostaining of TUNEL/CD31 signal (*yellow arrow*). Scale bar: 20 μm . (I) The quantification of TUNEL-positive cells of WT and A₁R KO mice is shown. Data in (B, D, F, I) are presented as mean \pm SEM. *** $P < 0.001$ (Student's *t*-test), comparing A₁R KO group with WT group.

cytokines such as interleukin-1 β (IL-1 β) and tumor necrosis factor- α , which lead to a delayed (~ 24 hours), marked, and sustained increase in adenosine receptor (particularly A_{2A}R and the A_{2B}R) expression in tissues and inflammatory cells.⁴³⁻⁴⁵ Locally increased adenosine levels and adenosine receptor signaling might represent a *local* “find-me” signal and service a unique “purinergic chemotaxis” for a *local* resolution to pathologic conditions (as revealed by genetic KO studies).¹⁰ Thus, the surge of adenosine level and the induction of adenosine receptors in the hypoxic phase of OIR¹¹ may constitute a negative feedback and defense mechanism countering such proangiogenic states triggered by hypoxia and HIF-1 α -mediated expression of VEGF in retina. Further dissection of the A₁R and A_{2A}R signaling interacting with the molecular and cellular pathways, leading to distinct physiological development and pathologic angiogenesis, is needed to fully understand this selectivity of A₁R and A_{2A}R control of OIR.

Adenosine A₁ Receptor Inactivation Reduces Hypoxia-Induced Vaso-obliteration by Attenuating Neural Apoptosis in Retina at P12

A hallmark of ROP is abnormal and excessive blood vessel growth, but paradoxically it is early vaso-obliteration that initiates proliferative retinopathy. Thus, preventing early retinal vessel loss at the hyperoxic phase can prevent the devastating latter stage (the hypoxic phase) of the disease. In the vaso-obliteration phase, hyperoxia induces apoptosis of ganglia and developing endothelial cells and inhibits endothelial cell proliferation and migration, resulting in vaso-obliteration.^{32,46} Notably, despite clear vaso-obliteration at the retina center in the hyperoxic phase, there is no “hypoxia” in retina as shown by *in vivo* detection with nitroimidazole EF5.⁴⁷ Since the adenosine concentration and the expression of ecto-5' nucleotidase (CD73) are low during the hyperoxic phase, we presumed that A₁Rs play a limited role at this stage. Surprisingly, we found that the avascular area and TUNEL-positive cells in the INL of retina in A₁R KO mice were reduced as compared to WT littermates, suggesting that A₁R activation probably aggravated hyperoxia-induced damage to developing retinal vessels by affecting neuronal apoptosis. Activation of retinal A₁Rs has been shown to inhibit Ca²⁺ channels in retinal ganglion cells of mini-slices,^{48,49} to protect NMDA-induced cell death in cultured retinal neurons,⁵⁰ and to mediate the IL-6 effect on the survival of cultured retinal ganglion cells.⁵¹ Consistent with the A₁R-mediated neuroprotective effect, early studies^{28,52,53} indicate that cytotoxicity and cell death are generally more pronounced in neurons and astrocytes derived from A₁R KO mice. Thus, additional studies are clearly warranted to clarify how A₁R KO may confer cellular protection at the hyperoxic phase of OIR. Nonetheless, our findings highlight for the first time the important function of adenosine-A₁Rs in modulating retinal vascular function even under hyperoxic environments with low extracellular adenosine level.

Adenosine A₁ Receptor Activation Is Required for Hypoxia-Driven Physiological Revascularization, but Not Neovascularization in Retina at P17

In the vaso-proliferation phase of OIR, both regrowth of normal (intraretinal) revascularization and pathologic (intravitreal) angiogenesis occur during P12 to P17, the former promoting retinal vascular recovery but the latter resulting in pathologic neovascularization tufts. Current research on ROP has been largely focused on the mechanism that drives pathologic (intravitreal) neovascularization in the retina and treatment strategies to stop it.^{1,2,4,9} On the other hand, intraretinal revascularization has received much less attention.⁵⁴ An early study⁵⁵ has reported that the A₁R agonist CPA increases membrane vessel in the chick chorioallantoic membrane model. This study provides the first *in vivo* demonstration that A₁R activation is critical to beneficial intraretinal revascularization at the hypoxic phase by showing that A₁R inactivation increases the avascular area without changes in neovascularization.

Control of retinal vascularization during development and OIR likely involves close interactions among neurons, astrocytes, microglial cells, and endothelial cells. Impairment in beneficial intraretinal revascularization by genetic deletion of the A₁R can be attributed to several factors such as reduced endothelial cell proliferation, increased intravitreal neovascularization, and increased cell apoptosis, leading to reduced astrocytic functions or reduced tip cell formation. Despite the fact that ROP is fundamentally a vascular proliferating disorder, our findings suggest that cell proliferation and vitreal neovascularization tufts are apparently not important factors for A₁R control of intraretinal revascularization. Moreover, control of avascular area in A₁R KO mice is also not associated with cellular apoptosis, since the numbers of TUNEL-positive cells at P17 were comparable between WT and A₁R KO groups. Similarly, retinal inflammatory response is unlikely a major contributing factor in A₁R control of retinal vascularization and retinopathy, since microglial activation was not affected by A₁R inactivation. Astrocytes play a significant role in angiogenesis in response to hypoxia through their high expression of VEGF.⁵⁷ Indeed, studies in OIR models have shown that the density of astrocytes in the retina decreases during hyperoxia and then increases following hypoxia,^{56,57} and that restoring retinal astrocytes reduces vascular pathology associated with OIR.^{40,58} However, our analysis revealed that the GFAP-positive cells (astrocytes) in retina at P17 were indistinguishable between WT and A₁R KO mice. Thus, under our experimental condition, cell types other than astrocytes are likely responsible for the A₁R-mediated modulation of hypoxia-induced intraretinal vascularization.

At the tips of vascular sprouts with long filopodia are endothelial tip cells that play an important role in developmental blood vessel formation and physiological revascularization.⁵⁹ In retina, endothelial tip cells are mainly located at the leading edge of vascular plexus and the fusion sites of the remodeling area.⁶⁰ In sprouting angiogenesis, though, the filopodia of endothelial tip cells participate in intercellular communication, cell migration, and cell adhesion to lead the




FIGURE 5. Genetic deletion of A₁R did not affect microglial and astrocytic activation but reduced formation of endothelial tip cells at P17. **(A)** Microglial activation in retina was assessed by immunohistochemistry of Iba-1 expression during OIR. The expression of Iba-1 was detected by immunohistochemistry in mainly the GCL and INL layers of retina. Iba-1-positive cells are indicated by yellow arrows. Scale bar: 20 μm. **(B)** The quantification of Iba-1-positive cells in retina of WT ($n = 7$ retinas from seven mice) and KO ($n = 7$ retinas from seven mice) is shown. Data are presented as the mean \pm SEM. **(C)** The number of astrocytes of WT and A₁R KO retinas at P17 of OIR was determined by GFAP immunofluorescence staining. The GFAP-positive cells are indicated by yellow arrows. Scale bar: 20 μm. **(D)** The GFAP-positive cells of retinas from WT ($n = 7$ retinas from seven mice) and KO ($n = 7$ retinas from seven mice) were quantified and presented as mean \pm SEM. **(E)** Hypoxia-induced growth of endothelial tip cells and astrocytes in retina of WT and A₁R KO mice at P17 of OIR was stained with isolectin B4 and anti-GFAP, respectively. Representative retinal endothelial tip cells are indicated by yellow arrows. Scale bar: 20 μm. **(F)** Higher magnifications of the regions from WT retina (the yellow pane) are shown. The interactions between endothelial tip cells and GFAP-positive astrocytes were indicated by their close contact between these cells. Scale bar: 10 μm. **(G)** The number of endothelial tip cells in WT and A₁R KO groups was quantified. Data are presented as mean \pm SEM. ** $P < 0.01$ for comparing A₁R KO group with WT group ($n = 7$ retinas from seven mice for each group).




FIGURE 6. Genetic deletion of A₁Rs reduced retinal normal vascularization at P21 of OIR. (A) Retinal blood vessels of both WT and KO groups were visualized by isolectin B4 staining of whole-mount retinas at P21 of OIR. The whole retinal surface is shown by *white dotted line*. Avascular area is indicated as *yellow*. Scale bar: 500 μm. (B) Avascular area (%) was quantified as a percentage of the whole retinal surface ($n = 7$ retinas from seven mice for each group). Data are presented as the mean \pm SEM. $*P < 0.05$, Student's *t*-test.

outgrowth of blood vessels toward the gradients of VEGF-A.⁶¹ Consistent with this functional view of tip cells, we detected filopodia of endothelial tip cells that were closely attached to the astrocytes in retina. Importantly, our analysis revealed that the quantity of endothelial tip cells is reduced by genetic deletion of the A₁R at P17. Thus, activation of A₁Rs promotes revascularization by increasing the number of endothelial tip cells, with normal morphology of filopodia to ensure vascular extension in the right direction along the astrocyte template. Whether the A₁R control of tip cells is achieved by a direct effect of A₁Rs in tip cells or an indirect effect of A₁Rs in neurons (by stimulating platelet derived growth factor) or astrocytes (by releasing VEGF) on tip cells needs to be clarified in future studies. Moreover, future studies of A₁R control of expression of the tip cell-specific candidate genes that are significantly upregulated in the tip cell fraction of sprouting vessels in a mouse model of OIR⁶² would shed light on the transcriptional mechanism underlying A₁R control of tip cells in promoting retinal vascularization.

Adenosine A₁ Receptor Inactivation Promotes Retinal Normal Vascularization at P21 of OIR

As further demonstration of the stage-specific effect of A₁R inactivation, we uncovered that A₁R activation at the P17 to P21 period apparently slows down retinal vascularization in OIR model. This new level of complexity of A₁R activity reinforces the notion that adenosine acting at A₁Rs exerts distinct functions at different courses of the disease (P12, P17, and P21). Distinct effects of A₁R KO at P12, P17, and P21 may be due to the different levels of adenosine and different cellular populations involved in these different processes. Consequently, adenosine-based therapeutic strategy should be disease-stage-specific.

In summary, the findings that A₁Rs (this study) and A_{2A}Rs¹⁵ selectively modulate OIR without affecting normal retinal vascular development confer a critical advantage for the proposed adenosine receptor-based therapeutic strategy over other treatment strategies (such as anti-VEGF antibody) that also compromise normal retinal vasculature during development. We uncovered distinct A₁R control of hyperoxia-induced vaso-obliteration at P12 and hypoxia-induced revascularization at P17 by acting on neurons and tip cells. These findings advance the prospective of adenosine receptor-based therapy for ROP with two novel strategies: (1) to reduce hyperoxia-induced retinal vessel loss (with A₁R antagonists) to effectively control OIR, rather than direct inhibition of pathologic (intravitreal) neovascularization; and (2) to promote intraretinal revascularization (with A₁R agonists) at the hypoxic phase, thus shifting from blocking pathologic intravitreal neovascularization toward beneficial intraretinal revascularization. From the translational perspective, it would be interesting to study the genetic association between the single nucleotide polymorphism of the human genes encoding the A₁ receptor (AdoraA1) and ROP, as revealed in other pathologic conditions such as apnea of prematurity,⁶³ ischemic cardiomyopathy,⁶⁴ and development of posttraumatic seizures.⁶⁵ Lastly, the demonstration of the distinct and coordinated control of OIR by retinal A₁Rs and A_{2A}Rs also provides biological basis for the clinical finding that the use of caffeine (the nonselective A₁R and A_{2A}R antagonist) in treatment of apnea in premature infants is associated with reduced ROP in a 2-year follow-up study.

Acknowledgments

The authors thank Jing Lin (Mount Sinai School of Medicine, New York, NY, USA) for his critical reading of the manuscript.

Supported by the Start-up Fund from Wenzhou Medical University (No. 89211010; No. 89212012), the Zhejiang Provincial Special Funds (No. 604161241), Key Laboratory of Vision Science, Ministry of Health, China (No. 601041241), the National Key Basic Research Program of China (2012CB910402), the Central Government Special Fund for Local Universities' Development (No. 474091314), National Natural Science Foundation of China (No. 81100672), and Zhejiang Provincial Natural Science Foundation (LY12H12007) and by US National Institutes of Health Grants (DK095862, HL095556, and HL108922) and Boston University School of Medicine Special Research Fund DTD 4-30-14.

Disclosure: **S. Zhang**, None; **H. Li**, None; **B. Li**, None; **D. Zhong**, None; **X. Gu**, None; **L. Tang**, None; **Y. Wang**, None; **C. Wang**, None; **R. Zhou**, None; **Y. Li**, None; **Y. He**, None; **M. Chen**, None; **Y. Huo**, None; **X.-L. Liu**, None; **J.-F. Chen**, None

References

- Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. *Prog Retin Eye Res.* 2008;27:331-371.
- Cavallaro G, Filippi L, Bagnoli P, et al. The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge. *Acta Ophthalmol.* 2014;92:2-20.
- Clark D, Mandal K. Treatment of retinopathy of prematurity. *Early Hum Dev.* 2008;84:95-99.
- Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. *New Engl J Med.* 2011;364:603-615.
- Tokunaga CC, Mitton KP, Dailey W, et al. Effects of anti-VEGF treatment on the recovery of the developing retina following oxygen-induced retinopathy. *Invest Ophthalmol Vis Sci.* 2014; 55:1884-1892.
- Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. *Arch Ophthalmol.* 2012;130:1000-1006.
- Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. *Am J Pathol.* 2007;171:53-67.
- Saint-Geniez M, Maharaj AS, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. *PLoS One.* 2008;3: e3554.
- Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. *New Engl J Med.* 2012;367: 2515-2526.
- Chen JF, Eltzschig HK, Fredholm BB. Adenosine receptors as drug targets—what are the challenges? *Nat Rev Drug Discov.* 2013;12:265-286.
- Lutty GA, McLeod DS. Retinal vascular development and oxygen-induced retinopathy: a role for adenosine. *Prog Retin Eye Res.* 2003;22:95-111.
- Takagi H, King GL, Robinson GS, Ferrara N, Aiello LP. Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells. *Invest Ophthalmol Vis Sci.* 1996;37:2165-2176.
- Taomoto M, McLeod DS, Merges C, Lutty GA. Localization of adenosine A_{2a} receptor in retinal development and oxygen-induced retinopathy. *Invest Ophthalmol Vis Sci.* 2000;41:230-243.
- Lutty GA, Merges C, McLeod DS. 5' nucleotidase and adenosine during retinal vasculogenesis and oxygen-induced retinopathy. *Invest Ophthalmol Vis Sci.* 2000;41:218-229.
- Liu XL, Zhou R, Pan QQ, et al. Genetic inactivation of the adenosine A_{2A} receptor attenuates pathological but not developmental angiogenesis in the mouse retina. *Invest Ophthalmol Vis Sci.* 2010;51:6625-6632.
- Cui D, Trier K, Zeng J, Wu K, Yu M, Ge J. Adenosine receptor protein changes in guinea pigs with form deprivation myopia. *Acta Ophthalmol.* 2010;88:759-765.
- Brito R, Pereira MR, Paes-de-Carvalho R, Calaza Kda C. Expression of A₁ adenosine receptors in the developing avian retina: in vivo modulation by A_{2A} receptors and endogenous adenosine. *J Neurochem.* 2012;123:239-249.
- Ibrahim AS, El-Shishtawy MM, Zhang W, Caldwell RB, Liou GI. A_{2A} adenosine receptor (A_{2A}AR) as a therapeutic target in diabetic retinopathy. *Am J Pathol.* 2011;178:2136-2145.
- Ahmad S, Fatteh N, El-Sherbiny NM, et al. Potential role of A_{2A} adenosine receptor in traumatic optic neuropathy. *J Neuroimmunol.* 2013;264:54-64.
- Liou GI, Auchampach JA, Hillard CJ, et al. Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A_{2A} adenosine receptor. *Invest Ophthalmol Vis Sci.* 2008;49:5526-5531.
- Santiago AR, Baptista FI, Santos PF, et al. Role of microglia adenosine A_{2A} receptors in retinal and brain neurodegenerative diseases. *Mediators Inflamm.* 2014;2014:465694.
- Mino RP, Spoerri PE, Caballero S, et al. Adenosine receptor antagonists and retinal neovascularization in vivo. *Invest Ophthalmol Vis Sci.* 2001;42:3320-3324.
- Grant MB, Davis MI, Caballero S, Feoktistov I, Biaggioni I, Belardinelli L. Proliferation, migration, and ERK activation in human retinal endothelial cells through A_{2B} adenosine receptor stimulation. *Invest Ophthalmol Vis Sci.* 2001;42: 2068-2073.
- Grant MB, Tarnuzzer RW, Caballero S, et al. Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells. *Circ Res.* 1999;85:699-706.
- Afzal A, Shaw LC, Caballero S, et al. Reduction in preretinal neovascularization by ribozymes that cleave the A_{2B} adenosine receptor mRNA. *Circ Res.* 2003;93:500-506.
- Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity. *New Engl J Med.* 2007;357:1893-1902.
- Charles BA, Conley YP, Chen G, et al. Variants of the adenosine A_{2A} receptor gene are protective against proliferative diabetic retinopathy in patients with type 1 diabetes. *Ophthalmic Res.* 2011;46:1-8.
- Johansson B, Halldner L, Dunwiddie TV, et al. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A₁ receptor. *Proc Natl Acad Sci U S A.* 2001;98:9407-9412.
- Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. *Invest Ophthalmol Vis Sci.* 1994;35: 101-111.
- Connor KM, Krah NM, Dennison RJ, et al. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. *Nat Protoc.* 2009;4:1565-1573.
- Suchting S, Freitas C, le Noble F, et al. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. *Proc Natl Acad Sci U S A.* 2007;104:3225-3230.
- Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. *Nat Med.* 1995;1:1024-1028.
- Duan LJ, Takeda K, Fong GH. Prolyl hydroxylase domain protein 2 (PHD2) mediates oxygen-induced retinopathy in neonatal mice. *Am J Pathol.* 2011;178:1881-1890.
- Ludewig P, Flachsbarth K, Wegscheid C, et al. CEACAM1 confers resistance toward oxygen-induced vessel damage in a mouse model of retinopathy of prematurity. *Invest Ophthalmol Vis Sci.* 2014;55:7950-7960.

35. Narayanan SP, Xu Z, Putluri N, et al. Arginase 2 deficiency reduces hyperoxia-mediated retinal neurodegeneration through the regulation of polyamine metabolism. *Cell Death Dis.* 2014;5:e1075.
36. Gendron RL, Good WV, Miskiewicz E, Tucker S, Phelps DL, Paradis H. Tubedown-1 (Tbdn-1) suppression in oxygen-induced retinopathy and in retinopathy of prematurity. *Mol Vis.* 2006;12:108-116.
37. Dorrell MI, Friedlander M. Mechanisms of endothelial cell guidance and vascular patterning in the developing mouse retina. *Prog Retin Eye Res.* 2006;25:277-295.
38. Dorrell MI, Aguilar E, Friedlander M. Retinal vascular development is mediated by endothelial filopodia, a preexisting astrocytic template and specific R-cadherin adhesion. *Invest Ophthalmol Vis Sci.* 2002;43:3500-3510.
39. Scott A, Powner MB, Gandhi P, et al. Astrocyte-derived vascular endothelial growth factor stabilizes vessels in the developing retinal vasculature. *PLoS One.* 2010;5:e11863.
40. Weidemann A, Krohne TU, Aguilar E, et al. Astrocyte hypoxic response is essential for pathological but not developmental angiogenesis of the retina. *Glia.* 2010;58:1177-1185.
41. Luty GA, McLeod DS, Bhutto I, Wiegand SJ. Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog. *Invest Ophthalmol Vis Sci.* 2011;52:4039-4047.
42. Elsherbiny NM, Naime M, Ahmad S, et al. Potential roles of adenosine deaminase-2 in diabetic retinopathy. *Biochem Biophys Res Commun.* 2013;436:355-361.
43. Frick JS, MacManus CF, Scully M, Glover LE, Eltzschig HK, Colgan SP. Contribution of adenosine A2B receptors to inflammatory parameters of experimental colitis. *J Immunol.* 2009;182:4957-4964.
44. Schingnitz U, Hartmann K, Macmanus CF, et al. Signaling through the A2B adenosine receptor dampens endotoxin-induced acute lung injury. *J Immunol.* 2010;184:5271-5279.
45. Linden J. Regulation of leukocyte function by adenosine receptors. *Adv Pharmacol.* 2011;61:95-114.
46. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. *N Engl J Med.* 1994;331:1480-1487.
47. Scott A, Fruttiger M. Oxygen-induced retinopathy: a model for vascular pathology in the retina. *Eye (Lond).* 2010;24:416-421.
48. Sun X, Barnes S, Baldrige WH. Adenosine inhibits calcium channel currents via A1 receptors on salamander retinal ganglion cells in a mini-slice preparation. *J Neurochem.* 2002;81:550-556.
49. Santos PF, Caramelo OL, Carvalho AP, Duarte CB. Adenosine A1 receptors inhibit Ca²⁺ channels coupled to the release of ACh, but not of GABA, in cultured retina cells. *Brain Res.* 2000;852:10-15.
50. Oku H, Goto W, Kobayashi T, et al. Adenosine protects cultured retinal neurons against NMDA-induced cell death through A1 receptors. *Curr Eye Res.* 2004;29:449-455.
51. Perigolo-Vicente R, Ritt K, Pereira MR, Torres PM, Paes-de-Carvalho R, Giestal-de-Araujo E. IL-6 treatment increases the survival of retinal ganglion cells in vitro: the role of adenosine A1 receptor. *Biochem Biophys Res Commun.* 2013;430:512-518.
52. Bjorklund O, Shang M, Tonazzini I, Dare E, Fredholm BB. Adenosine A1 and A3 receptors protect astrocytes from hypoxic damage. *Eur J Pharmacol.* 2008;596:6-13.
53. Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. *Annu Rev Neurosci.* 2001;24:31-55.
54. Wan T, Xu Z, Zhou HJ, et al. Functional analyses of TNFR2 in physiological and pathological retina angiogenesis. *Invest Ophthalmol Vis Sci.* 2013;54:211-221.
55. Clark AN, Youkey R, Liu X, et al. A1 adenosine receptor activation promotes angiogenesis and release of VEGF from monocytes. *Circ Res.* 2007;101:1130-1138.
56. Chan-Ling T, Tout S, Hollander H, Stone J. Vascular changes and their mechanisms in the feline model of retinopathy of prematurity. *Invest Ophthalmol Vis Sci.* 1992;33:2128-2147.
57. Downie LE, Pianta MJ, Vingrys AJ, Wilkinson-Berka JL, Fletcher EL. AT1 receptor inhibition prevents astrocyte degeneration and restores vascular growth in oxygen-induced retinopathy. *Glia.* 2008;56:1076-1090.
58. Dorrell MI, Aguilar E, Jacobson R, et al. Maintaining retinal astrocytes normalizes revascularization and prevents vascular pathology associated with oxygen-induced retinopathy. *Glia.* 2010;58:43-54.
59. Xu Z, Gong J, Maiti D, et al. MEF2C ablation in endothelial cells reduces retinal vessel loss and suppresses pathologic retinal neovascularization in oxygen-induced retinopathy. *Am J Pathol.* 2012;180:2548-2560.
60. Gerhardt H, Golding M, Fruttiger M, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. *J Cell Biol.* 2003;161:1163-1177.
61. Wood W, Martin P. Structures in focus—filopodia. *Int J Biochem Cell Biol.* 2002;34:726-730.
62. del Toro R, Prahst C, Mathivet T, et al. Identification and functional analysis of endothelial tip cell-enriched genes. *Blood.* 2010;116:4025-4033.
63. Kumral A, Tuzun F, Yesilirmak DC, Duman N, Ozkan H. Genetic basis of apnoea of prematurity and caffeine treatment response: role of adenosine receptor polymorphisms: genetic basis of apnoea of prematurity. *Acta Paediatr.* 2012;101:e299-e303.
64. Tang Z, Diamond MA, Chen JM, et al. Polymorphisms in adenosine receptor genes are associated with infarct size in patients with ischemic cardiomyopathy. *Clin Pharmacol Ther.* 2007;82:435-440.
65. Wagner AK, Miller MA, Scanlon J, Ren D, Kochanek PM, Conley YP. Adenosine A1 receptor gene variants associated with post-traumatic seizures after severe TBI. *Epilepsy Res.* 2010;90:259-272.